Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice.
Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice.
复制标题
DOI：
10.1111/j.1750-2659.2010.00155.x
复制
发表时间：
2010-09
影响因子：
4.4
通讯作者：
Aldridge JR
中科院分区：
文献类型：
--
作者：
Moseley CE;Webster RG;Aldridge JR
请引用本文：Moseley等人。(2010)过氧化体增殖物激活受体和AMP激活的蛋白激酶激动剂可保护小鼠免受致命流感病毒的攻击。流感和其他呼吸道病毒4(5)，307-311。背景：甲型H1N1流感病毒是从北美人类中分离到的一种新的甲型H1N1流感病毒，现已发展成为21世纪的第一次大流行( )。有关全球抗病毒药物短缺、抗药性流感病毒变异株的演变以及疫苗供应延迟6个月的报道，突显了开发新疗法的必要性，这些疗法可能会在未来的大流行期间广泛传播。方法 为了寻找传统治疗策略的替代方案，我们筛选了几类可能减轻流感病毒诱导的免疫病理效应的免疫调节剂。结果在这里，我们提供了两类药物的初步证据，即过氧化物酶体增殖物激活受体- 激动剂和γ激活的蛋白激酶激动剂，对感染高致病性和大流行流感病毒株的小鼠具有保护作用。结论 在发达国家的广泛生产，再加上这里所述的显著保护程度，使这些药物成为一种潜在的治疗选择，可以广泛应用于对抗未来流感流行或大流行引起的严重疾病。
Please cite this paper as: Moseley et al. (2010) Peroxisome proliferator‐activated receptor and AMP‐activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza and Other Respiratory Viruses 4(5), 307–311. Background A novel influenza A (H1N1) virus was isolated from humans in North America and has developed into the first pandemic of the 21st century. Reports of a global shortage of antiviral drugs, the evolution of drug‐resistant influenza virus variants, and a 6‐month delay in vaccine availability underline the need to develop new therapeutics that may be widely distributed during future pandemics. Methods In an effort to discover alternatives to the conventional therapeutic strategies available, we screened several classes of immunomodulatory agents possessing the potential to mitigate the effects of influenza virus‐induced immunopathology. Results Here, we provide preliminary evidence that two classes of drugs, peroxisome proliferator‐activated receptor‐γ agonists and AMP‐activated protein kinase agonists, provide protection in mice infected with highly pathogenic and pandemic strains of influenza virus. Conclusions The extensive production in the developed world, combined with the significant degree of protection described here, establishes these drugs as a potential therapeutic option that may be broadly implemented to combat serious disease caused by future influenza epidemics or pandemics.
登录
查看更多内容
影响因子：
120.7
作者：
Dharan, Nila J.;Gubareva, Larisa V.;Fry, Alicia M.
通讯作者：
Fry, Alicia M.
影响因子：
11.8
作者：
Fedson DS
通讯作者：
Fedson DS
影响因子：
--
作者：
Basler, Christopher F.
通讯作者：
Basler, Christopher F.
DOI：
10.1016/s1473-3099(08)70070-7
发表时间：
2008-09
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Fedson DS
通讯作者：
Fedson DS
影响因子：
4.4
作者：
Herold, Susanne;von Wulffen, Werner;Lohmeyer, Juergen
通讯作者：
Lohmeyer, Juergen